BOULDER, Colo. & BEVERLY, Mass.--(BUSINESS WIRE)--Today, Enzymatics launches two new targeted next generation sequencing assays for detecting and identifying fusions in NTRK and FGFR gene families. The FusionPlex™ NTRK and FGFR assays use Enzymatics’ proprietary NGS-based fusion detection technology, Anchored Multiplex PCR (AMP™), to detect and identify fusions and mutations without prior knowledge of breakpoints or fusion partners from minute amounts of various sample types. The panels will join the ALK, RET, ROS1 panel, the Heme panel, and the Sarcoma panel as the newest additions to the Archer™ FusionPlex™ product line.
Help employers find you! Check out all the jobs and post your resume.
